Silence Therapeutics names Max Herrmann CFO
This article was originally published in Scrip
Executive Summary
Silence Therapeutics (UK) has named Max Herrmann chief financial officer and company secretary, effective 4 May. He has more than 20 years' biotechnology and pharmaceutical industry experience, having previously served as chief financial officer at Intercytex Group. Before that he spent more than 10 years as a sell-side equity analyst, most recently as managing director and head of European pharmaceutical and biotechnology research at ING. Silence completed its merger with Intradigm in January.